Published in Antimicrob Agents Chemother on May 01, 1992
Selection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ABT-538, a novel protease inhibitor. J Virol (1995) 3.05
Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease. Antimicrob Agents Chemother (1996) 2.13
Resistance to human immunodeficiency virus type 1 protease inhibitors. Antimicrob Agents Chemother (1998) 1.92
Regulation of human immunodeficiency virus type 1 Env-mediated membrane fusion by viral protease activity. J Virol (2004) 1.89
Defining the level of human immunodeficiency virus type 1 (HIV-1) protease activity required for HIV-1 particle maturation and infectivity. J Virol (1995) 1.78
Antiviral therapy for human immunodeficiency virus infections. Clin Microbiol Rev (1995) 1.49
HIV-1 Gag processing intermediates trans-dominantly interfere with HIV-1 infectivity. J Biol Chem (2009) 1.47
Effect of retroviral proteinase inhibitors on Mason-Pfizer monkey virus maturation and transmembrane glycoprotein cleavage. J Virol (1992) 1.46
Determinants of the human immunodeficiency virus type 1 p15NC-RNA interaction that affect enhanced cleavage by the viral protease. J Virol (1997) 1.22
Conserved cysteines of the human immunodeficiency virus type 1 protease are involved in regulation of polyprotein processing and viral maturation of immature virions. J Virol (1999) 0.98
Analysis and characterization of dimerization inhibition of a multi-drug-resistant human immunodeficiency virus type 1 protease using a novel size-exclusion chromatographic approach. Biochem J (2009) 0.85
Antiretroviral activities of protease inhibitors against murine leukemia virus and simian immunodeficiency virus in tissue culture. Antimicrob Agents Chemother (1993) 0.84
Processing of the envelope glycoprotein gp160 in immunotoxin-resistant cell lines chronically infected with human immunodeficiency virus type 1. J Virol (1995) 0.78
Oxidative modifications of kynostatin-272, a potent human immunodeficiency virus type 1 protease inhibitor: potential mechanism for altered activity in monocytes/macrophages. Antimicrob Agents Chemother (2002) 0.77
Monitoring processed, mature Human Immunodeficiency Virus type 1 particles immediately following treatment with a protease inhibitor-containing treatment regimen. AIDS Res Ther (2005) 0.75
A multi-drug resistant HIV-1 protease is resistant to the dimerization inhibitory activity of TLF-PafF. J Mol Graph Model (2014) 0.75
Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (1970) 1528.65
Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci U S A (1979) 365.71
Complete nucleotide sequence of the AIDS virus, HTLV-III. Nature (1985) 30.62
Isolation and properties of Moloney murine leukemia virus mutants: use of a rapid assay for release of virion reverse transcriptase. J Virol (1981) 13.11
Role of capsid precursor processing and myristoylation in morphogenesis and infectivity of human immunodeficiency virus type 1. Proc Natl Acad Sci U S A (1989) 12.54
In vitro mutagenesis identifies a region within the envelope gene of the human immunodeficiency virus that is critical for infectivity. J Virol (1988) 12.52
Nucleotide sequence and expression of an AIDS-associated retrovirus (ARV-2). Science (1985) 10.97
Active human immunodeficiency virus protease is required for viral infectivity. Proc Natl Acad Sci U S A (1988) 10.77
Rosette-forming human lymphoid cell lines. I. Establishment and evidence for origin of thymus-derived lymphocytes. J Natl Cancer Inst (1972) 10.15
Standardized and simplified nomenclature for proteins common to all retroviruses. J Virol (1988) 6.31
Genomic diversity of human T-lymphotropic virus type III (HTLV-III). Science (1985) 5.33
Role of human immunodeficiency virus type 1-specific protease in core protein maturation and viral infectivity. J Virol (1989) 5.15
Rational design of peptide-based HIV proteinase inhibitors. Science (1990) 4.57
Sequence homology and morphologic similarity of HTLV-III and visna virus, a pathogenic lentivirus. Science (1985) 4.31
Biochemical and immunological analysis of human immunodeficiency virus gag gene products p17 and p24. J Virol (1988) 4.06
Human immunodeficiency virus protease expressed in Escherichia coli exhibits autoprocessing and specific maturation of the gag precursor. Proc Natl Acad Sci U S A (1987) 3.72
Interaction between the human T-cell lymphotropic virus type IIIB envelope glycoprotein gp120 and the surface antigen CD4: role of carbohydrate in binding and cell fusion. Proc Natl Acad Sci U S A (1987) 3.47
Interferon-alpha but not AZT suppresses HIV expression in chronically infected cell lines. Science (1989) 3.43
Immunological and chemical analysis of P6, the carboxyl-terminal fragment of HIV P15. AIDS Res Hum Retroviruses (1987) 3.03
HIV enhancer activity perpetuated by NF-kappa B induction on infection of monocytes. Nature (1991) 2.97
Design, activity, and 2.8 A crystal structure of a C2 symmetric inhibitor complexed to HIV-1 protease. Science (1990) 2.83
A synthetic HIV-1 protease inhibitor with antiviral activity arrests HIV-like particle maturation. Science (1990) 2.80
An inhibitor of the protease blocks maturation of human and simian immunodeficiency viruses and spread of infection. Proc Natl Acad Sci U S A (1990) 2.32
Processing of the precursor of NF-kappa B by the HIV-1 protease during acute infection. Nature (1991) 2.18
Morphometric analysis of recombinant soluble CD4-mediated release of the envelope glycoprotein gp120 from HIV-1. AIDS Res Hum Retroviruses (1990) 2.13
Inhibition of HIV-1 protease in infected T-lymphocytes by synthetic peptide analogues. Nature (1990) 2.13
Enzyme inhibition in relation to chemotherapy. Proc Soc Exp Biol Med (1949) 1.92
Tight-binding inhibitors-I. Kinetic behavior. Biochem Pharmacol (1975) 1.89
Human T-cell lymphotropic virus type III: immunologic characterization and primary structure analysis of the major internal protein, p24. J Virol (1985) 1.82
Inhibition of human immunodeficiency virus 1 protease in vitro: rational design of substrate analogue inhibitors. Proc Natl Acad Sci U S A (1989) 1.47
HIV-1 proteinase is required for synthesis of pro-viral DNA. Biochem Biophys Res Commun (1991) 1.00
HIV. Tampering with transcription. Nature (1991) 0.93
Detection of HIV-1 neutralizing antibodies by a simple, rapid, colorimetric assay. AIDS Res Hum Retroviruses (1988) 0.89
Rapid and sensitive colorimetric method for visualizing biotin-labeled DNA probes hybridized to DNA or RNA immobilized on nitrocellulose: Bio-blots. Proc Natl Acad Sci U S A (1983) 12.81
Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase. Proc Natl Acad Sci U S A (1986) 8.48
Type-specific neutralization of the human immunodeficiency virus with antibodies to env-encoded synthetic peptides. Proc Natl Acad Sci U S A (1988) 7.74
Detection of viral genomes in cultured cells and paraffin-embedded tissue sections using biotin-labeled hybridization probes. Virology (1983) 7.54
Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein. Proc Natl Acad Sci U S A (1989) 6.58
HTLV-III/LAV-neutralizing antibodies to an E. coli-produced fragment of the virus envelope. Science (1986) 6.33
A novel murine oncornavirus with dual eco- and xenotropic properties. Proc Natl Acad Sci U S A (1975) 5.91
Prospect for prevention of human immunodeficiency virus infection: purified 120-kDa envelope glycoprotein induces neutralizing antibody. Proc Natl Acad Sci U S A (1986) 5.55
A proposed nomenclature for the virion proteins of oncogenic RNA viruses. Virology (1974) 5.01
Restricted neutralization of divergent human T-lymphotropic virus type III isolates by antibodies to the major envelope glycoprotein. Proc Natl Acad Sci U S A (1986) 4.68
Broadly neutralizing antibodies elicited by the hypervariable neutralizing determinant of HIV-1. Science (1990) 4.43
Binding of soluble CD4 proteins to human immunodeficiency virus type 1 and infected cells induces release of envelope glycoprotein gp120. Proc Natl Acad Sci U S A (1991) 4.40
Neutralizing antibodies to an immunodominant envelope sequence do not prevent gp120 binding to CD4. J Virol (1988) 4.13
Association of viral reverse transcriptase with an enzyme degrading the RNA moiety of RNA-DNA hybrids. Nat New Biol (1971) 3.95
Identification of a novel aspartic protease (Asp 2) as beta-secretase. Mol Cell Neurosci (1999) 3.77
Human immunodeficiency virus protease expressed in Escherichia coli exhibits autoprocessing and specific maturation of the gag precursor. Proc Natl Acad Sci U S A (1987) 3.72
Assembly of type C oncornaviruses: a model. Science (1978) 3.53
Interaction between the human T-cell lymphotropic virus type IIIB envelope glycoprotein gp120 and the surface antigen CD4: role of carbohydrate in binding and cell fusion. Proc Natl Acad Sci U S A (1987) 3.47
Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection. J Infect Dis (1997) 3.35
A molecular clasp in the human immunodeficiency virus (HIV) type 1 TM protein determines the anti-HIV activity of gp41 derivatives: implication for viral fusion. J Virol (1995) 3.11
Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. Proc Natl Acad Sci U S A (1996) 3.07
Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers. Proc Natl Acad Sci U S A (1997) 3.02
Construction of an infectious molecular clone of the autonomous parvovirus minute virus of mice. J Virol (1983) 2.95
Localization of RNA tumor virus polypeptides. I. Isolation of further virus substructures. Virology (1973) 2.94
Sequence-specific cleavage of single-stranded DNA: oligodeoxynucleotide-EDTA X Fe(II). Proc Natl Acad Sci U S A (1985) 2.54
Human T-cell lymphotropic virus IIIB glycoprotein (gp120) bound to CD4 determinants on normal lymphocytes and expressed by infected cells serves as target for immune attack. Proc Natl Acad Sci U S A (1987) 2.53
Ribonucleic acid components of BAI strain A (myeloblastosis) avian tumor virus. Cancer Res (1967) 2.53
Polypeptides of avian RNA tumor viruses. 1. Isolation and physical and chemical analysis. Virology (1970) 2.49
A single amino acid change in the cytoplasmic domain of the simian immunodeficiency virus transmembrane molecule increases envelope glycoprotein expression on infected cells. J Virol (1995) 2.35
Isolation of the major viral glycoprotein and a putative precursor from cells transformed by avian sarcoma viruses. Proc Natl Acad Sci U S A (1974) 2.15
Morphometric analysis of recombinant soluble CD4-mediated release of the envelope glycoprotein gp120 from HIV-1. AIDS Res Hum Retroviruses (1990) 2.13
gamma-Vinyl GABA (4-amino-hex-5-enoic acid), a new selective irreversible inhibitor of GABA-T: effects on brain GABA metabolism in mice. J Neurochem (1977) 2.13
Inhibition of HIV-1 protease in infected T-lymphocytes by synthetic peptide analogues. Nature (1990) 2.13
Polypeptides of avian RNA tumor viruses. IV. Components of the viral envelope. Virology (1972) 2.09
An internalization signal in the simian immunodeficiency virus transmembrane protein cytoplasmic domain modulates expression of envelope glycoproteins on the cell surface. J Cell Biol (1996) 2.06
Human chromosome 12 is required for elevated HIV-1 expression in human-hamster hybrid cells. Science (1989) 2.03
Polymorphism of the 3' open reading frame of the virus associated with the acquired immune deficiency syndrome, human T-lymphotropic virus type III. Nucleic Acids Res (1985) 2.01
Autoradiographic distribution of hematoporphyrin derivative in normal and tumor tissue of the mouse. Cancer Res (1981) 2.01
The principal neutralization determinant of simian immunodeficiency virus differs from that of human immunodeficiency virus type 1. Proc Natl Acad Sci U S A (1992) 2.00
Expression of human tissue factor under the control of the mouse tissue factor promoter mediates normal hemostasis in knock-in mice. J Thromb Haemost (2007) 2.00
HIV-1 membrane fusion mechanism: structural studies of the interactions between biologically-active peptides from gp41. Biochemistry (1996) 1.91
Purification and properties of thiol beta-lactamase. A mutant of pBR322 beta-lactamase in which the active site serine has been replaced with cysteine. J Biol Chem (1984) 1.88
A conserved region at the COOH terminus of human immunodeficiency virus gp120 envelope protein contains an immunodominant epitope. Proc Natl Acad Sci U S A (1987) 1.87
Gene expression during reactivation of herpes simplex virus type 1 from latency in the peripheral nervous system is different from that during lytic infection of tissue cultures. J Virol (1997) 1.86
Expression and site-specific mutagenesis of the poliovirus 3C protease in Escherichia coli. Proc Natl Acad Sci U S A (1986) 1.76
Neutralization of homologous and heterologous oncornaviruses by antisera against the p15(E) and gp71 polypeptides of Friend murine leukemia virus. Virology (1976) 1.73
A bifunctional thymidylate synthetase-dihydrofolate reductase in protozoa. Mol Biochem Parasitol (1984) 1.71
Purification and characterization of the bifunctional thymidylate synthetase-dihydrofolate reductase from methotrexate-resistant Leishmania tropica. Biochemistry (1985) 1.71
Evidence that a precursor glycoprotein is cleaved to yield the major glycoprotein of avian tumor virus. J Virol (1977) 1.70
Humoral immune response to the entire human immunodeficiency virus envelope glycoprotein made in insect cells. Proc Natl Acad Sci U S A (1987) 1.70
Isolation of proteins by gel filtration in 6M guanidinium chloride: application to RNA tumor viruses. Anal Biochem (1974) 1.70
Physicochemical dissociation of CD4-mediated syncytium formation and shedding of human immunodeficiency virus type 1 gp120. J Virol (1993) 1.68
Identification of sites within gp41 that serve as targets for antibody-dependent cellular cytotoxicity by using human monoclonal antibodies. J Immunol (1990) 1.68
Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. The NIAID AIDS Vaccine Clinical Trials Network. J Infect Dis (1993) 1.67
Phenotypic variation in the response to the human immunodeficiency virus among derivatives of the CEM T and WIL-2 B cell lines. J Exp Med (1988) 1.67
CD8+ T lymphocyte-mediated inhibition of HIV-1 long terminal repeat transcription: a novel antiviral mechanism. AIDS Res Hum Retroviruses (1993) 1.66
An analysis of type-C retrovirus polypeptides and their associations in the virion. Virology (1978) 1.65
Comparative chemical properties of avian oncornavirus polypeptides. Virology (1975) 1.64
Polypeptides of mammalian oncornaviruses. II Characterization of murine leukemia virus polypeptide (p 15) bearing interspecies reactivity. Virology (1975) 1.63
The effect of 4-amino hex-5-ynoic acid (gamma-acetylenic GABA, gammma-ethynyl GABA) a catalytic inhibitor of GABA transaminase, on brain GABA metabolism in vivo. J Neurochem (1977) 1.63
Human immunodeficiency virus-1 protease. 2. Use of pH rate studies and solvent kinetic isotope effects to elucidate details of chemical mechanism. Biochemistry (1991) 1.63
Polyvalent human immunodeficiency virus synthetic immunogen comprised of envelope gp120 T helper cell sites and B cell neutralization epitopes. J Immunol (1989) 1.63
Human immunodeficiency virus 1 protease expressed in Escherichia coli behaves as a dimeric aspartic protease. Proc Natl Acad Sci U S A (1989) 1.60
4-amino-hex-5-enoic acid, a selective catalytic inhibitor of 4-aminobutyric-acid aminotransferase in mammalian brain. Eur J Biochem (1977) 1.59
Polypeptides of mammalian oncornaviruses. I. Isolation and serological analysis polypeptides from murine and feline C-type viruses. Virology (1973) 1.59
HIV-1 GP120-mediated immune suppression and lymphocyte destruction in the absence of viral infection. J Immunol (1989) 1.57
Purification and serological characterization of the major envelope glycoprotein from AKR murine leukemia virus and its reactivity with autogenous immune sera from mice. J Virol (1976) 1.56
Expression of murine leukemia virus structural antigens on the surface of chemically induced murine sarcomas. Proc Natl Acad Sci U S A (1974) 1.54
Peptide substrates and inhibitors of the HIV-1 protease. Biochem Biophys Res Commun (1989) 1.52
Polypeptides of avian RNA tumor viruses. V. Analysis of the virus core. Virology (1972) 1.51
Use of biotinylated probes for detecting sickle cell anemia. Clin Chem (1985) 1.50
Alteration of HIV-1 infectivity and neutralization by a single amino acid replacement in the V3 loop domain. AIDS Res Hum Retroviruses (1991) 1.50
Purification and biochemical characterization of recombinant simian immunodeficiency virus protease and comparison to human immunodeficiency virus type 1 protease. Biochemistry (1991) 1.50
A direct relationship between the partitioning of the pathogenic prion protein and transmissible spongiform encephalopathy infectivity during the purification of plasma proteins. Transfusion (2001) 1.49
Polypeptides of mammalian oncornaviruses. III. Localization of p 15 and reactivity with natural antibody. Virology (1975) 1.48
Expression of the Major Viral Glycoprotein of Avian Tumor Virus in Cells of chf(+) Chicken Embryos. J Virol (1975) 1.48
Inhibition of human immunodeficiency virus 1 protease in vitro: rational design of substrate analogue inhibitors. Proc Natl Acad Sci U S A (1989) 1.47
Effect of retroviral proteinase inhibitors on Mason-Pfizer monkey virus maturation and transmembrane glycoprotein cleavage. J Virol (1992) 1.46
Serological responses in chimpanzees inoculated with human immunodeficiency virus glycoprotein (gp120) subunit vaccine. Proc Natl Acad Sci U S A (1987) 1.46
In vivo myocardial protection from ischemia/reperfusion injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone. Circulation (2001) 1.46
Evidence that antibody-mediated neutralization of human immunodeficiency virus type 1 by sera from infected individuals is independent of coreceptor usage. J Virol (1998) 1.43
Biological, immunological, and biochemical evidence that HIX virus is a recombinant between Moloney leukemia virus and a murine xenotropic C type virus. Virology (1978) 1.42
Kinetic mechanism of Escherichia coli glutamine synthetase. Biochemistry (1980) 1.42
Macrophage accumulation in mice is inhibited by low molecular weight products from murine leukemia viruses. J Immunol (1980) 1.41
Isolation and characterization of two group-specific antigens from feline leukemia virus. Virology (1971) 1.41
Identification of human T cell leukemia virus in a Japanese patient with adult T cell leukemia and cutaneous lymphomatous vasculitis. Proc Natl Acad Sci U S A (1983) 1.41
Single-organism model of host defense against infection: a novel immunotoxicologic approach to evaluate immunomodulatory drugs. Toxicol Pathol (1997) 1.40
Soluble CD4 and dextran sulfate mediate release of gp120 from HIV-1: implications for clinical trials. J Acquir Immune Defic Syndr (1991) 1.38